EP1379132A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number
EP1379132A4
EP1379132A4 EP02760994A EP02760994A EP1379132A4 EP 1379132 A4 EP1379132 A4 EP 1379132A4 EP 02760994 A EP02760994 A EP 02760994A EP 02760994 A EP02760994 A EP 02760994A EP 1379132 A4 EP1379132 A4 EP 1379132A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02760994A
Other languages
German (de)
French (fr)
Other versions
EP1379132A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1379132A2 publication Critical patent/EP1379132A2/en
Publication of EP1379132A4 publication Critical patent/EP1379132A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02760994A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1379132A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008278 WO2002102994A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1379132A2 EP1379132A2 (en) 2004-01-14
EP1379132A4 true EP1379132A4 (en) 2009-07-01

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications After (5)

Application Number Title Priority Date Filing Date
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1381622A2 (en)
AU (6) AU2002354719A1 (en)
CA (7) CA2441840A1 (en)
WO (7) WO2002095010A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2629442T3 (en) 1998-06-01 2017-08-09 Agensys, Inc. New transmembrane serpentine antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
BR0007556A (en) 1999-01-15 2001-10-23 Biogen Inc Tweak and tweak receptor antagonists and their use to treat immune disorders
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
AU2002243444A1 (en) 2000-10-31 2002-06-24 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
ES2532757T3 (en) 2001-09-06 2015-03-31 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2463596A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
CA2542017A1 (en) * 2003-10-14 2005-05-06 Baxter International, Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
KR101268877B1 (en) 2004-09-01 2013-05-31 다이나박스 테크놀로지 코퍼레이션 Methods and compositions for inhibition of innate immune responses and autoimmunity
WO2006026807A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
CA2579705A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006089613A1 (en) 2005-02-28 2006-08-31 Baxter International Inc. Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
JP2008532544A (en) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) * 2005-09-01 2011-04-13 Florey Howard Inst Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ES2636089T3 (en) 2006-10-27 2017-10-05 Genentech, Inc. Antibodies and immunoconjugates and uses for them
CN101636179B (en) 2006-11-07 2012-10-10 默沙东公司 Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (en) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (en) 2009-10-30 2012-08-15 默沙东公司 AX213 and AX132 PCSK9 antagonists and variants
CN103153346A (en) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 Methods of treatment using tlr7 and/or tlr9 inhibitors
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7456605B2 (en) 2016-12-23 2024-03-27 プレジデント アンド フェローズ オブ ハーバード カレッジ PCSK9 gene editing
JP7247101B2 (en) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to STEAP-1
EP3641951B1 (en) 2017-06-22 2023-09-20 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
EP3642383B1 (en) * 2017-06-22 2022-12-21 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Also Published As

Publication number Publication date
WO2003038063A3 (en) 2003-12-11
WO2002090526A2 (en) 2002-11-14
AU2002326293A1 (en) 2003-01-02
WO2003004622A2 (en) 2003-01-16
WO2003038063A2 (en) 2003-05-08
WO2002095010A2 (en) 2002-11-28
EP1414845A4 (en) 2009-07-08
AU2002324424A1 (en) 2002-12-03
AU2002354719A1 (en) 2003-01-21
WO2002102994A2 (en) 2002-12-27
CA2441416A1 (en) 2003-01-16
WO2002076488A1 (en) 2002-10-03
AU2002363296A1 (en) 2003-05-12
WO2002102993A2 (en) 2002-12-27
EP1390390A4 (en) 2009-07-08
EP1423134A2 (en) 2004-06-02
EP1379264A1 (en) 2004-01-14
WO2002090526A3 (en) 2003-10-30
WO2002102994A3 (en) 2003-07-24
AU2002332391A1 (en) 2003-01-02
AU2002320013A1 (en) 2002-11-18
EP1381622A2 (en) 2004-01-21
WO2002102993A3 (en) 2004-03-25
EP1390390A2 (en) 2004-02-25
CA2441702A1 (en) 2002-12-27
EP1379264A4 (en) 2009-07-08
CA2441840A1 (en) 2002-11-28
WO2002095010A3 (en) 2004-02-12
CA2441755A1 (en) 2003-05-08
CA2441417A1 (en) 2002-11-14
EP1414845A2 (en) 2004-05-06
EP1379132A2 (en) 2004-01-14
EP1404702A4 (en) 2009-07-08
CA2441397A1 (en) 2002-10-03
WO2003004622A3 (en) 2004-02-19
CA2441832A1 (en) 2002-12-27
EP1404702A2 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
EP1379132A4 (en) Human secreted proteins
EP1408759A4 (en) Human secreted proteins
EP1251863A4 (en) 22 human secreted proteins
AU2002361452A8 (en) Secreted proteins
GB0218205D0 (en) Human ZZAP1 protein
IL162598A0 (en) Secreted protein
AU2002232596A1 (en) Secreted human proteins
AU2002354803A8 (en) Secreted proteins
EP1368468A4 (en) 83 human secreted proteins
AU2003301843A8 (en) 157 human secreted proteins
EP1385977A4 (en) Secreted proteins
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (en) 70 human secreted proteins
EP1417224A4 (en) Secreted proteins
AU2002365153A1 (en) 41 human secreted proteins
EP1404807A4 (en) 20 human secreted proteins
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A8 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2002303843A8 (en) Secreted proteins
AU2003211136A8 (en) 6 human secreted proteins
AU2002253985A1 (en) 83 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
EP1443818A4 (en) Novel secreted proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20090527BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090903